Medical Device Global Market Access

Pure Global

Navigate every market. Accelerate every launch.

Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut.

Why listen?
• Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck.
• First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale.
• Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve.
• Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag.
• AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors.

What you’ll hear
• Launching SaMD under multiple risk classes in parallel
• Surviving an unannounced ISO 13485 audit
• Building a “reg-first” QMS that scales
• Mastering Latin-American registrations without endless language cycles
• Leveraging real-world evidence to shorten clinical timelines
• Aligning cybersecurity, privacy, and post-market surveillance rules across regions

Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue.

⸻

Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

Play

Open in

50 episodes
daily
Avg 5 min
English

Episodes 50

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Yesterday · 5 min
China NMPA's Dynamic Adjustment of Medical Device Classification: What Manufacturers Need to Know
This episode details China NMPA's new 'dynamic adjustment' mechanism for medical device classification, introduced in Announcements No. 52 and 53 on September 8, 2026. We explain how this shift from a static catalog to a fluid, data-driven system impacts manufacturers. The host covers the new concept of 'transitional periods' for reclassified devices and provides practical actions for regulatory and quality teams to adapt their strategies for long-term compliance and market access in China. Key Questions: - What is the new 'dynamic adjustment' mechanism for medical device classification in China? - How do NMPA Announcements No. 52 and 53 from September 8, 2026, change the regulatory landscape? - Who is affected by these new classification rules? - What is a 'transitional period' and how does it work for reclassified devices? - Why is continuous monitoring of NMPA announcements more important than ever? - How can manufacturers prepare for a potential up-classification of their products? - What are the strategic benefits of a device being down-classified? - What practical steps should regulatory teams take to adapt to this new framework? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvmng_lLLOcl15OQwwefymbsVWpE95523gy2JxWppal10Y0Q5iLS89zdMEOdWFNNhyrY7q-SWllEoFsJ9VhVPyNJK2v5BXl_7ijI0PrtA8SPoVzdKGhdLF9so66aixRBfgNyNys0uTYSRIAg3Jyp_Nfi64KML8t-LCSsNqdLbAWKVcGJGGQfHKqFmRe6eA5ag_YQXG6E0V1tiNCOAtXd6D5Dw2MaaDsBYKMG5zAGApT1iCrFm502v0zQ4gvnU= How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory environments like China's. Our local experts and AI-powered tools provide continuous regulatory monitoring to track changes like the NMPA's new dynamic classification system. We assist with regulatory strategy, technical dossier preparation, and local representation to ensure your products remain compliant throughout their lifecycle. Whether you're entering the market or managing an existing portfolio, we streamline the process. Learn more about our end-to-end solutions at https://pureglobal.com, contact us at info@pureglobal.com, and explore our free AI tools and database at https://pureglobal.ai.
Friday · 4 min
SFDA Medical Device Advertising: Responding to Enforcement in Saudi Arabia
On September 6, 2026, the Saudi Food and Drug Authority (SFDA) announced legal action against a medical device company for misleading advertising. This episode breaks down the SFDA's announcement, the core principles of Saudi Arabia's medical device advertising regulations, and the potential consequences of non-compliance. We provide practical, actionable steps for manufacturers to audit their promotional materials and implement robust internal controls to ensure all marketing claims are substantiated and align with their device's approved indications. Key Questions: - What recent enforcement action did the Saudi FDA take against misleading device advertising? - Which types of advertising claims are drawing SFDA scrutiny? - What are the core principles of SFDA's medical device advertising regulations? - What are the potential legal and financial consequences of non-compliance? - How can you ensure your marketing materials are aligned with your device's approved indications? - What is the role of clinical evidence in substantiating promotional claims in Saudi Arabia? - What internal processes should your company implement to mitigate advertising risks? - How should regulatory and marketing teams collaborate on promotional content review? Sources: - https://www.sfda.gov.sa/en/news How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access or maintain their presence in global markets like Saudi Arabia. Our experts offer strategic guidance on regulatory requirements, including advertising and promotion, and use advanced AI tools to efficiently compile, manage, and submit technical dossiers. We act as your local representative, ensuring ongoing compliance with post-market obligations and monitoring regulatory changes that could impact your business. Whether you're a startup or a multinational, we streamline your path to market. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
Thursday · 4 min
Australia TGA Device Classification Rules: Saline Flush Syringes Reclassified to Class IIa
Australia's Therapeutic Goods Administration (TGA) has introduced a new classification rule, Clause 2.2, that reclassifies non-invasive devices containing only saline for flushing or maintaining another device, such as pre-filled saline syringes, to Class IIa. This episode details the scope of the new rule, the critical compliance date of September 7, 2026, for new applications, and the five-year transition period for devices already on the Australian Register of Therapeutic Goods (ARTG). We provide practical steps for manufacturers to ensure compliance with these updated TGA device classification rules. Key Questions: - What is the new TGA Clause 2.2 and which specific combination products does it affect? - Why have pre-filled saline flush syringes been reclassified to Class IIa in Australia? - What is the effective date for new device applications to comply with this rule? - How long is the transition period for existing devices already on the ARTG? - What are the immediate impacts on a manufacturer's Quality Management System (QMS)? - What evidence is required for a Class IIa submission to the TGA? - How does this change align Australian regulations with other global markets? - What are the first steps your regulatory team should take to prepare for this change? Sources: - https://www.nationaltribune.com.au/updated-classification-rules-for-certain-combination-products/ - https://www.tga.gov.au/news/news/updated-classification-rules-certain-combination-products How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to navigate complex market changes like the TGA's new classification rules. Our experts offer end-to-end support, including developing regulatory strategies for new submissions, creating transition plans for existing products, and compiling Class IIa technical dossiers. By leveraging our local Australian expertise and advanced AI tools, we streamline the submission process, ensuring your products meet all TGA requirements efficiently. Whether you're launching a new device or managing a legacy portfolio, we can help you maintain compliance and secure your market presence in Australia. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.
Wednesday · 4 min
China NMPA Approves LEQEMBI Autoinjector: A Signal for Drug-Device Combination Products
This episode examines the September 3, 2026, approval of the LEQEMBI (lecanemab) subcutaneous autoinjector by China's NMPA. We explore how this shift from bi-weekly IV infusions to once-weekly at-home administration impacts Alzheimer's treatment and what the NMPA's use of the Priority Review pathway signals to manufacturers of innovative drug-device combination products seeking access to the Chinese market. Key Questions: - What are the key differences between the new subcutaneous LEQEMBI formulation and the previous intravenous version? - Why did the NMPA grant this application a Priority Review? - What does this approval indicate about the NMPA's stance on innovative drug delivery systems? - How does this decision affect the treatment landscape for early Alzheimer's disease in China? - What precedent does this set for other manufacturers of drug-device combination products? - What specific types of data, like human factors studies, are crucial for NMPA submissions of autoinjectors? - What practical steps should regulatory teams take in response to this approval? Sources: - https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-subcutaneous-formulation-initiation How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, including those with complex drug-device combination products. We help you navigate the NMPA regulatory landscape with services like market access strategy, technical dossier compilation using advanced AI, and local representation in China. Our experts can guide you through the submission process, including leveraging pathways like Priority Review, to get your innovative products to market faster. Visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI regulatory tools and global product database at https://pureglobal.ai.
Tuesday · 5 min
Brazil ANVISA High-Risk Device Registration: Public Consultation No. 1,248 Explained
This episode details Brazil ANVISA's Public Consultation No. 1,248, published on August 26, 2026, which proposes a new regulatory framework for the registration of Class III and IV high-risk medical devices. We discuss the key changes to technical documentation requirements, the move to align with international standards, the impact on manufacturers and their Brazilian Registration Holders (BRH), and the critical 45-day feedback period closing in October 2026. Learn the practical steps your regulatory and quality teams should take now to prepare for these significant updates to Brazil's market access requirements. Key Questions: - What is ANVISA's Public Consultation No. 1,248 and why is it important for device manufacturers? - Which specific medical device classes are affected by this proposed Brazilian regulation? - How will technical dossier requirements for high-risk devices change under the new proposal? - What is the deadline for submitting feedback to ANVISA on these proposed changes? - What are the new requirements for clinical evidence, risk management, and software validation? - How does this proposal aim to align Brazil's regulations with international standards like IMDRF? - What are the four key actions manufacturers should take immediately to prepare? - What role does the Brazilian Registration Holder (BRH) play in this new process? Sources: - https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/cp-propoe-nova-regra-para-registro-de-dispositivos-medicos - https://www.gov.br/anvisa/pt-br/assuntos/consultas-publicas/consultas-publicas-em-andamento How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in Brazil and over 30 other markets, developing efficient regulatory strategies and preparing technical dossiers for submission to authorities like ANVISA. Our team of local experts, supported by advanced AI, helps you navigate complex requirements, maintain compliance, and accelerate your time to market. For support with your Brazilian market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.
Monday · 5 min
Brazil ANVISA's New Notification Guidance: What Class I/II Medical Device and IVD Manufacturers Need to Know
Brazil's ANVISA has published two new guidance manuals detailing the 'notification' pathway for Class I and II medical devices and IVDs. This episode explains how these manuals, released on August 25, 2023, clarify the submission processes under RDC 751/2022 and RDC 830/2023, what practical information they contain for manufacturers, and the concrete steps regulatory teams should take to streamline market access for lower-risk products in Brazil. Key Questions: - What are the new ANVISA guidance manuals for the notification pathway? - Which medical device and IVD classes are affected by this new guidance? - How does this guidance clarify the submission process under RDC 751/2022 and RDC 830/2023? - What specific documentation is required for a notification submission in Brazil? - How should manufacturers use ANVISA's electronic portal for notifications? - What are the rules for grouping multiple devices in a single submission? - What are the post-market responsibilities for notified devices in Brazil? - What practical steps should my regulatory team take in response to this new guidance? Sources: - https://www.asphalion.com/news/anvisa-publishes-two-guidance-manuals-for-the-regularisation-of-medical-devices/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in Brazil and over 30 other markets, managing submissions and ensuring ongoing compliance. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, helping you navigate complex requirements like ANVISA's notification pathway. From initial market research to post-market surveillance, we ensure your products reach global markets faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.
September 6 · 5 min
Singapore HSA's New Registration Pathway for Special Access Route (SAR) Devices
Singapore's Health Sciences Authority (HSA) launched a Registration Support Initiative on August 28, 2026, to help transition clinically important medical devices from the Special Access Route (SAR) to full market registration. This episode details the purpose of this new pathway, the eligibility criteria for devices serving small patient populations, the significant evaluation-fee waiver, and the inaugural application deadline of December 31, 2026. We provide practical steps for manufacturers to leverage this opportunity to secure a sustainable, registered supply route in Singapore. Key Questions: - What is Singapore's Special Access Route (SAR) and why is it not a long-term solution for market access? - What is the purpose of the new HSA Registration Support Initiative launched in August 2026? - Which medical devices are eligible to transition from SAR to full registration under this new pathway? - What are the key benefits for manufacturers, including the full waiver of evaluation fees? - What is the critical inaugural application deadline that companies must meet? - What evidence is needed to demonstrate a device's clinical importance for a small patient population in Singapore? - How does prior approval from a comparable overseas regulator impact eligibility for the initiative? - What practical steps should regulatory and market-access teams take now to prepare a submission? Sources: - https://gpc-gateway.com/2026/08/31/singapore-introduces-fee-supported-registration-pathway-for-clinically-important-medical-devices/ How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as a local representative in over 30 markets, develop efficient regulatory strategies, and use AI to compile and submit technical dossiers. Our services help you gain and maintain market access through continuous regulatory monitoring and post-market surveillance. Whether you are a startup or a multinational enterprise, Pure Global provides a single, efficient process to access multiple international markets. Learn more about our free AI tools and global database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com to accelerate your market entry.
September 5 · 4 min
UK MHRA Health Bill Amendments 2026: New Powers for Future Device Regulation
The UK government has proposed three amendments to the Health Bill, introduced on September 1, 2026, that grant significant new powers to the MHRA. This episode breaks down what these changes—enhanced information sharing, agile regulatory updates via secondary legislation, and the foundation for a future UK-specific device licensing system—mean for medical device manufacturers. We discuss the strategic implications for companies relying on CE marking for UK market access and outline practical steps that regulatory and quality teams should take now to prepare for Great Britain's move toward a sovereign regulatory framework. Key Questions: - What new powers are proposed for the UK MHRA in the 2026 Health Bill? - How will the MHRA's ability to share information with the wider healthcare system change? - What does "agile regulation" mean for medical device manufacturers in the UK? - Is the UK moving away from reliance on the UKCA and CE marks for device approval? - When were these amendments introduced and what is the legislative timeline? - How do these changes affect companies currently using a CE mark for UK market access? - What foundational steps are being taken to create a future UK device licensing system? - What practical actions should regulatory teams take now to prepare for these changes? Sources: - https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill - https://medtech.pharmaintelligence.informa.com/MT151249/MHRA-May-Get-Wider-Device-Licensing-Powers-As-UK-Eyes-New-Regulatory-Regime - https://commonslibrary.parliament.uk/research-briefings/cbp-9999/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure ongoing compliance. By combining in-country expertise with advanced AI, we help you navigate complex and evolving landscapes like the UK's move toward a sovereign system. Prepare your business for future requirements and accelerate your market entry with our technology-driven solutions. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
September 4 · 5 min
UK MHRA's New Licensing Powers: What the 2026 Health Bill Amendments Mean for Medical Device Manufacturers
This episode explores the significant amendments to the UK Health Bill introduced on September 1, 2026, which grant the MHRA new powers to establish a future medical device licensing regime. We analyze the potential shift from the current system of third-party UK Approved Bodies to a direct licensing model where the MHRA would approve devices. We discuss the long-term implications for manufacturers' market access strategies in Great Britain, who is affected, and the practical steps regulatory teams should consider for this evolving landscape. Key Questions: - What are the new powers granted to the UK MHRA under the 2026 Health Bill amendments? - How could the UK's medical device approval process change from a third-party model to a direct licensing system? - Who is affected by this potential new regulatory framework in Great Britain? - What is the significance of the September 1, 2026 date for medical device manufacturers? - How does this proposed change impact long-term market access strategies for the UK? - What are the potential benefits and challenges of an MHRA-led direct licensing regime? - What practical steps should regulatory teams take now to prepare for these future changes? - Why is it crucial to monitor MHRA consultations and announcements moving forward? Sources: - https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill--2 - https://medtech.citeline.com/MT153453/MHRA-May-Get-Wider-Device-Licensing-Powers-As-UK-Eyes-New-Regulatory-Regime How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative and help you navigate complex regulatory landscapes like the evolving UK system. Our experts, combined with advanced AI tools, develop efficient strategies for market approval and maintain compliance through post-market surveillance. Whether you're a startup or a multinational, we can help you prepare for changes like the MHRA's potential shift to direct licensing. Visit https://pureglobal.com, email us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your market entry.
September 3 · 5 min
UK MHRA Non-Compliant Devices: DSI/2026/007 and Supply Chain Risks
The UK's MHRA has issued Device Safety Information notice DSI/2026/007, warning of non-compliant medical devices on the UK market lacking valid UKCA or CE marking. This episode breaks down the immediate actions required for healthcare providers and suppliers, such as quarantining suspect products and reporting to the MHRA. We also explore the critical implications for manufacturers, focusing on the need for enhanced post-market surveillance and rigorous supply chain oversight to prevent patient risk and ensure compliance with UK MDR 2002. Key Questions: - What is the significance of the UK MHRA's Device Safety Information notice DSI/2026/007? - Which devices are affected by this non-compliance warning? - What immediate steps must UK healthcare providers and distributors take? - How does this notice impact a manufacturer's post-market surveillance obligations? - Why is supply chain oversight more critical than ever for devices in the UK? - What are the risks of having non-compliant devices on the market? - How can manufacturers audit their UK distribution channels effectively? - What role does UDI and proper labeling play in preventing this issue? - What are the long-term regulatory implications for market access in the UK? Sources: - https://www.gov.uk/government/publications/mhra-safety-roundup-august-2026 How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts provide strategic guidance on UKCA marking, post-market surveillance, and supply chain management to ensure ongoing compliance. We act as your local representative and use advanced AI to streamline technical dossier preparation and submission. Whether you're a startup or a multinational, we can help you navigate the complexities of the UK market. Visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.
September 2 · 4 min
Australia TGA Consultation on Medical Device Information Sharing: What Sponsors Need to Know
Australia's Therapeutic Goods Administration (TGA) has launched a consultation on proposals to increase the public sharing of medical device information. This episode breaks down the TGA's initiative, which was announced on August 13, 2026, and explores its potential impact on manufacturers and sponsors. We discuss the types of information that may become public, the implications for post-market surveillance and data management, and the crucial feedback deadline of October 2, 2026. Learn the practical steps your team should take now to prepare for a future of greater transparency in the Australian market. Key Questions: - What specific information does the TGA propose to make public about medical devices? - How will these changes impact the obligations of Australian sponsors and manufacturers? - What is the deadline for providing feedback on this important TGA consultation? - How could increased transparency affect post-market surveillance and reporting requirements? - What steps should regulatory teams take now to prepare for these potential changes? - Will commercially sensitive information be protected under the new proposals? - How does this Australian initiative align with global trends in medical device transparency? - What are the TGA's stated goals for improving the sharing of medical device information? Sources: - https://www.tga.gov.au/news/news/consultation-improving-sharing-information-about-medical-devices - https://www.tga.gov.au/resources/consultations/consultation-sharing-more-information-about-medical-devices How Pure Global can help: Pure Global helps MedTech and IVD companies access global markets faster. Navigating regulatory shifts like the TGA's proposal for greater transparency requires local expertise and a proactive strategy. We act as a local representative in Australia and over 30 other markets, providing continuous regulatory monitoring to keep you ahead of changes. Our experts and AI-powered tools streamline the creation of technical dossiers, manage post-market surveillance, and help you develop a robust strategy for compliance and market access. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.
September 1 · 5 min
Health Canada Special Access Program: New Application Process for Medical Devices
Health Canada has modernized the application process for its Medical Devices Special Access Program (SAP) as of August 24, 2026. This episode details the two key changes: the introduction of a new accessible PDF application form and a new secure online submission method. We explore Health Canada's goals to reduce errors, improve data security, and accelerate review times for unauthorized devices needed for patients with serious conditions, outlining the practical steps for healthcare professionals and manufacturers. Key Questions: - What is Health Canada's Special Access Program for medical devices? - What specific changes were announced for the SAP application process on August 24, 2026? - Why did Health Canada introduce a new PDF application form? - What are the benefits of the new secure online submission method? - Who is primarily affected by these SAP application changes? - How can manufacturers and healthcare professionals prepare for this new process? - What common errors is the new system designed to prevent? - What practical steps should regulatory teams take right now? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html - https://www.smart-mdr.com/health-canada-announces-changes-to-special-access-program-application-process-for-medical-devices/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies achieve faster global market access. We act as your local representative in over 30 markets, including Canada, developing efficient regulatory strategies and using advanced AI to compile and manage technical submissions. Our experts ensure ongoing compliance through post-market surveillance and continuous regulatory monitoring. For support with the Canadian SAP process or other market access challenges, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and extensive device database at https://pureglobal.ai.
August 31 · 4 min
UK MHRA ResMed Astral Alert: Ventilator Safety Actions for NatPSA/2026/004/MHRA
The UK's MHRA issued National Patient Safety Alert NatPSA/2026/004/MHRA on August 17, 2026, for ResMed Astral 100 and 150 ventilators manufactured before October 2024. A faulty internal supercapacitor can leak, causing the device to shut down unexpectedly and risking serious injury or death. This episode details the specific device fault, the risks to patients, and the mandatory actions required by the MHRA for healthcare providers and manufacturers. We focus on the critical importance of post-market surveillance and immediate risk mitigation for life-sustaining devices. Key Questions: - What is the specific defect in ResMed Astral ventilators identified by the MHRA? - Which device models and manufacturing dates are covered by NatPSA/2026/004/MHRA? - What are the immediate risks to patients in hospital and home care settings? - What actions must healthcare providers take to ensure patient safety? - How does this alert impact post-market surveillance obligations for manufacturers of life-sustaining devices? - What is the role of backup ventilation for affected patients? - How can teams document their response to this MHRA safety alert for compliance? - What lessons can be learned about component traceability and supplier quality management? Sources: - https://www.gov.uk/alerts-and-recalls/national-patient-safety-alert-resmed-astral-100-and-150-ventilators-potential-for-patient-harm-due-to-unexpected-interruption-of-ventilation-therapy-natpsa-2026-004-mhra - https://dispex.net/news-alerts/national-patient-safety-alert-resmed-astral-100-and-150-ventilators/ - https://www.gov.uk/government/publications/mhra-safety-roundup-august-2026/mhra-safety-roundup-august-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies, ensuring products meet safety and performance standards from development to post-market surveillance. Our experts help you establish robust post-market surveillance systems, manage incident reporting, and execute field safety corrective actions efficiently. With local representation in over 30 markets, including the UK, we act as your in-country contact with authorities like the MHRA, ensuring timely communication and compliance. Leverage our AI-powered tools and global database at https://pureglobal.ai to streamline your regulatory processes and maintain market access. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.
August 30 · 5 min
China NMPA Medical Device Approval: Analyzing the August 12, 2026 Batch
China's NMPA announced the approval of 122 medical devices on August 12, 2026, including many from leading international manufacturers such as Medtronic, Roche, and Siemens. This episode breaks down this significant regulatory event, analyzing the types of devices approved—from cardiovascular and IVDs to imaging and surgical tools. We explore what this large batch of approvals reveals about the NMPA's current review priorities, the opportunities available for foreign manufacturers, and the practical steps your regulatory and market access teams should take to leverage these insights for a successful China strategy. Key Questions: - What does the NMPA's latest batch of 122 device approvals mean for the Chinese market? - Which types of medical devices are being prioritized by Chinese regulators? - How can foreign manufacturers like Medtronic and Siemens find success in China? - What do these approvals reveal about the NMPA's review timelines and pathways? - Are there new opportunities for cardiovascular, IVD, or imaging devices in China? - What practical steps should my regulatory team take in response to this news? - How can we leverage this information for our China market access strategy? - Does this signal a shift in China's policy towards imported medical devices? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH02KbGyLdFMQfPN0_gVaWwc8YCTOtfEC-dbM5f0Jt-IBAMMrphnYEi5w8UKI1s8OoNRKu7vlRJ9ardRwtE9szhk3WH0WRsVoYrdgpq5qeq__bcflDwDPi7xcUqnvbxgL3S_3P1koNiqAyRZRhRR34= How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access the Chinese market. Our in-country experts in China and advanced AI technology streamline the NMPA registration process, from developing a robust regulatory strategy and compiling technical dossiers to managing local type testing and post-market surveillance. We act as your local representative, ensuring seamless communication with the NMPA and helping you navigate complex requirements to get your product to market faster. To learn more about our China market access solutions, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and global device database at https://pureglobal.ai.
August 29 · 5 min
Singapore HSA's New Medical Device Cybersecurity Guide (GL-10-R1): Key Principles and Actions
Singapore's Health Sciences Authority (HSA) has released its finalized 'Best Practices Guide for Medical Device Cybersecurity' (GL-10-R1), effective August 17, 2026. This episode explores the guide's three core principles—secure-by-design, shared responsibility, and transparency—and outlines their impact on manufacturers and healthcare providers. We discuss how these recommendations affect the total product lifecycle, from pre-market design to post-market surveillance, and provide actionable steps for regulatory, quality, and market-access teams to align with these new expectations. Key Questions: - What is the scope of Singapore HSA's new cybersecurity guide, GL-10-R1? - When does the new guidance become effective? - How does the 'secure-by-design' principle impact device development? - What does 'shared responsibility' mean for manufacturers and healthcare providers? - Why is transparency, including the use of an SBOM, now a best practice in Singapore? - Is compliance with this guide mandatory for pre-market device registration? - What are the expectations for post-market cybersecurity surveillance? - How can our team perform a gap analysis against these new recommendations? - What documentation changes are needed to align with the HSA's TPLC approach? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfeD51Gc0b8bXrqivrB1f_yGJ-oReepm1pwtUbCHvMVDMzBSGpP10xIL5VkgYs4NDhlHZU3XQ1R8FZ9pGI_k2Qf7XTrUr0r2h7hcYZTYd86gp2yGgNTzQG7bND_5OZSxuH2Wzf4ErQYG27cGNwR1hW2wJh75gaeyfNSCUJyTuDtr2TWgfKOs_-fS9Ws5c4juzk_x_xMeTh7-XsoDd3k-8EtMSXRuQIMVrXj2e-VHjgzzKeQGarhIAeSQCOpGA= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxa4zvDJJCRocH1oHTSnh2B2AAAHJFDoujOt2pFVcWf4NqOVo-qqozSujWIfe4EneSoW2xdyqpEItPSjWNBRdQGjhhYBRGThO9JaIHCPHC1PWye_Db_zmovuHxhdoWWNbfB-L0mYtRE6HxFgqDWHgNBnc441qzL_QrqwExqXPJRQNH6dmtzg== How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like Singapore's new cybersecurity guidance. We specialize in developing robust regulatory strategies, compiling and submitting technical dossiers, and implementing continuous regulatory monitoring to ensure your products remain compliant. Our combination of local expertise in over 30 markets and advanced AI technology streamlines the entire market access process, from initial gap analysis to post-market surveillance. For support with your global regulatory needs, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.
August 28 · 5 min
COFEPRIS Medical Device Sanitary Registry Viewer: What Manufacturers Need to Know
Mexico's health authority, COFEPRIS, has launched the Medical Device Sanitary Registry Viewer, a public digital tool for verifying device registrations. This episode explores how this platform, launched on August 20, 2026, enhances market transparency and simplifies compliance. We discuss how the tool works, its impact on manufacturers, distributors, and healthcare providers, and outline practical steps for regulatory teams to adapt to this new environment. Key Questions: - What is the new COFEPRIS Medical Device Sanitary Registry Viewer? - How does this public database impact market transparency in Mexico? - What specific information can be found using the new digital tool? - How does the viewer help combat counterfeit or unregistered medical devices? - What are the implications for manufacturers holding sanitary registrations? - How should distributors and importers change their compliance processes? - What steps should regulatory teams take to verify their product portfolios? - How does this initiative fit into COFEPRIS's broader digitalization strategy? Sources: - https://mexicobusiness.news/health/news/cofepris-opens-public-viewer-for-medical-device-registries How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory landscapes like Mexico's. Our local experts and advanced AI tools streamline market access, from initial strategy and technical dossier submission to acting as your official Local Representative. We ensure your registrations remain compliant amidst changes like the new COFEPRIS digital viewer through continuous regulatory monitoring. Whether you're a startup or a multinational, we accelerate your path to market. Learn more about our services, free AI tools, and global database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com.
August 27 · 4 min
India CDSCO Amends Sterilization Rules: What Removing the Loan Licence Means for Medical Devices
India's CDSCO has amended the Medical Devices Rules, 2017, effective August 24, 2024, removing the 'loan licence' requirement for manufacturers who outsource device sterilization. This episode explains the amendment, details the new mandatory labeling requirements for sterilized products, and outlines the practical steps that regulatory and quality teams must take during the six-month transition period to ensure compliance. Key Questions: - What was the 'loan licence' requirement for medical device sterilization in India? - How does the CDSCO's August 2024 amendment change the rules for outsourced sterilization? - Who is most affected by this regulatory update? - What are the new, specific labeling requirements for sterile medical devices? - What is the deadline for manufacturers to comply with these new labeling rules? - How does this change impact the relationship between manufacturers and third-party sterilization facilities? - What practical steps should regulatory teams take to ensure compliance? - Does this amendment simplify the market access process in India? Sources: - https://www.livemint.com/industry/pharma/govt-eases-medical-device-rules-speeds-access-to-eu-approved-products-11724508681177.html How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. For companies navigating changes like India's new sterilization rules, we provide expert regulatory strategy, technical dossier preparation, and local representation in over 30 markets. Our team helps ensure your labeling, QMS, and supplier agreements are fully compliant, minimizing delays and risks. Leverage our advanced AI tools and data-driven insights to manage submissions efficiently and maintain your market presence. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.
August 26 · 4 min
EU Notified Body Shake-Up: What the NSAI and TÜV NORD Exits Mean for MDR Certification
The EU Notified Body landscape was shaken in August 2024 with announcements that the National Standards Authority of Ireland (NSAI) will exit its MDR designation by 2026 and TÜV NORD Scandinavia has filed for bankruptcy. This episode breaks down the immediate impact on manufacturers certified by these bodies, the broader implications for Notified Body capacity under the MDR, and the critical strategic steps regulatory teams must take now to protect their EU market access. Key Questions: - What were the specific announcements from NSAI and TÜV NORD Scandinavia in August 2024? - Why is the National Standards Authority of Ireland (NSAI) exiting the MDR business by 2026? - What led to the bankruptcy of TÜV NORD Scandinavia so soon after its acquisition? - If your device is certified by NSAI or TÜV NORD, what are your immediate obligations? - How does this reduction in Notified Bodies impact overall MDR certification capacity in the EU? - What are the key differences between an 'orderly exit' and a bankruptcy for a Notified Body? - What practical steps should regulatory teams take right now to secure their CE marking? - How can manufacturers vet the long-term stability of a potential new Notified Body partner? Sources: - https://medtech.citeline.com/MT153434/NSAI-Will-Make-Orderly-Exit-From-MDR-Notified-Body-Business - https://medtech.citeline.com/MT153424/Low-Demand-Causes-TV-NORD-Scandinavia-Bankruptcy-Just-7-Months-After-Purchase How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like unexpected Notified Body changes. Our experts can develop an immediate-response strategy, manage the complex process of transferring your CE certification to a new Notified Body, and ensure your technical documentation is prepared for a smooth transition. We act as your local representative and leverage advanced AI tools to streamline submissions and monitor regulatory shifts, ensuring your market presence is secure. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and device database at https://pureglobal.ai.
August 25 · 5 min
Japan PMDA Workshop: A Guide to Medical Device Market Entry for U.S. Firms
Japan's PMDA and AdvaMed are hosting a free online workshop on September 1, 2026, for U.S.-based small and mid-sized medtech companies. This episode breaks down the significance of this direct engagement opportunity, covering the key topics on the agenda—including Japan's regulatory framework, scientific advice process, and review pathways. We discuss the strategic value for manufacturers and provide practical steps your regulatory and market access teams should take to maximize the benefits of this event and de-risk your entry into the Japanese market. Key Questions: - What is the upcoming PMDA and AdvaMed workshop and who should attend? - How can U.S. medtech SMEs benefit from this direct engagement with Japanese regulators? - What specific topics will the PMDA cover regarding Japan's regulatory framework? - Why is the scientific advice process in Japan crucial for a successful submission? - What are the key steps in the PMDA's medical device review process? - How can this event help de-risk your company's entry into the Japanese market? - What practical actions should your team take before and after the September 1, 2026 workshop? - What makes the Japanese medical device market both attractive and challenging? Sources: - https://www.advamed.org/events/entering-the-japanese-medical-device-market-regulatory-pathways-consultation-opportunities-and-practical-insights/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex markets like Japan. Our local experts and advanced AI tools streamline market access, from developing regulatory strategy and compiling technical dossiers to acting as your in-country representative. We help you get your products approved and maintain compliance efficiently, turning regulatory hurdles into market opportunities. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI regulatory tools and product database at https://pureglobal.ai to accelerate your global expansion.
August 24 · 4 min
UK MHRA Rectal Catheter Alert: Infant Safety and Post-Market Lessons
This episode examines the UK MHRA's Device Safety Information alert (DSI/2026/008), issued on August 18, 2026, which advises against the use of rectal catheters (gas/colic relievers) in infants. We explore why the MHRA took this precautionary action based on a lack of safety and efficacy data, rather than direct adverse event reports. The discussion focuses on the critical post-market surveillance lessons for manufacturers of direct-to-consumer medical devices, particularly those intended for vulnerable populations like children. Key Questions: - What is the UK MHRA's DSI/2026/008 and why was it issued? - Why are rectal catheters (gas/colic relievers) now considered unsafe for infants in the UK? - What does this alert mean for manufacturers and distributors of direct-to-consumer pediatric devices? - How does this MHRA action highlight the importance of proactive post-market surveillance? - What specific evidence did the MHRA find lacking for these devices? - What are the immediate steps regulatory and quality teams should take in response to this type of alert? - How can you strengthen your clinical data for devices intended for vulnerable populations? - Is this alert based on reported injuries, or is it a precautionary measure? Sources: - https://www.gov.uk/government/publications/rectal-catheters-sold-for-personal-use-gas-and-colic-relievers-do-not-use-in-infants-including-for-the-treatment-of-colic-gas-related-discomfort-or-constipation-dsi2026008 - https://www.rpharms.com/resources/news-and-updates/update-all-rectal-catheters-gas-and-colic-relievers-do-not-use-in-infants How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies navigating complex global markets like the UK. Our experts can help you develop a robust post-market surveillance (PMS) and post-market clinical follow-up (PMCF) strategy to ensure your products meet evolving regulatory expectations for safety and efficacy, especially for high-risk or vulnerable populations. We use advanced AI to compile technical dossiers, monitor regulatory changes, and ensure your labeling and clinical evidence are compliant. Whether you need to revise your regulatory strategy or manage submissions, we streamline the process for faster, more reliable market access. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

Showing 1–20 of 50 episodes